Cookies

Like most websites The Medicine Maker uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Subscribe to Newsletter
Pills concealed beneath cracking ice
Business & Regulation Biosimilars, Standards & Regulation

ICER Report Exposes Humira Price Hikes

The Institute for Clinical and Economic Review (ICER) has published the latest iteration of its annual Unsupported Price Increase Report, covering North American drug price rises in 2020 that ICER deems unjustified given a lack of corresponding improvements in efficacy or new clinical applications.

The independent body used a five-step selection process to arrive at a list of nine drugs with substantially high “unjustified” price increases. In the initial step, the 250 drugs with the highest US revenues were collated. Following a three-step narrowing-down process, three drugs were deemed to have sufficient evidence to support their price increases, whereas the remaining six increases were – according to ICER – unjustified.

The nine drugs in question were: AbbVie’s Humira and Lupron Depot; Supernus Pharmaceuticals’ Trokendi; Novartis’ Promacta; Vanda Pharmaceuticals’ Fanapt; Biogen’s Tysabri; Bausch Health’s Xifaxan; Horizon’s Krystexxa; and PTC Therapeutics’ Emflaza.

AbbVie’s Humira – an anti-inflammatory drug used for arthritis, Crohn’s disease, and other conditions – proved to be the worst offender, showing a 9.6 percent increase in net price that resulted in an additional US$1.4 billion of spending in the US. Combined with previous years’ reports, ICER found that Humira’s net price has increased by almost 30 percent since 2017. This stands in stark contrast with trends abroad, where competition from biosimilars has driven the price of Humira down. This tale of two trends may dissolve come 2023, when Humira biosimilars will enter the American market.

The report also included AbbVie’s protestations, in which the company argued that recent improvements to Humira justify the rises. ICER, however, was unimpressed. Its report states, “Of the 54 references submitted by the manufacturer, seven articles were duplicates and 23 were excluded because they did not meet our UPI review criteria. Of the remaining 24 articles, 18 presented previously known information about adalimumab, while the remaining six studies were considered low quality.”

Pills concealed under cracking ice
Image credit: cottonbro/Pexels.com | Julia Volk/Pexels.com | Justin Kauffman/Unsplash.com
Receive content, products, events as well as relevant industry updates from The Medicine Maker and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

About the Author
Angus Stewart

Associate Editor of The Medicine Maker

Between studying for my English undergrad and Publishing master's degrees I was out in Shanghai, teaching, learning, and getting extremely lost. Now I'm expanding my mind down a rather different rabbit hole: the pharmaceutical industry. Outside of this job I read mountains of fiction and philosophy, and I must say, it's very hard to tell who's sharper: the literati, or the medicine makers.

Related White Papers
MDRS used to confirm the pharmaceutical equivalence of Oral Solid Dose (OSD) products

| Contributed by Malvern Panalytical

Increase mAb purity with salt-tolerant cation exchanger

| Contributed by Tosoh

Early stage product development using laser diffraction analysis

| Contributed by Malvern Panalytical

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register